This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

THOUSAND OAKS, Calif., May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025.

A Delaware federal trial jury found Thousand Oaks, California-based drug company Amgen Inc. liable Thursday ... Jonathan Polkes and Adam B. Banks of White & Case; David E. Wilks and Scott B.

THOUSAND OAKS, Calif., May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

By Blake Brittain (Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to ...

Amgen Owes $406 Million for Monopolizing Cholesterol Drug Market, US Jury Says By Blake Brittain (Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor ...

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...